Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anemia
Pharma
After high-profile snub, Akebia plots vadadustat resubmission
Akebia plans to resubmit its application for vadadustat by the end of the third quarter.
Fraiser Kansteiner
Aug 24, 2023 10:40am
FibroGen CEO Enrique Conterno hits the exit after 3-year stint
Jul 25, 2023 2:02pm
ASCO: BMS' $4B plan for Reblozyl takes shape—with one caveat
May 25, 2023 5:00pm
FibroGen, AZ's anemia drug Evrenzo finally chalks up a win
May 18, 2023 11:24am
FibroGen's AZ deal in danger after anemia drug fails in 2nd act
May 5, 2023 9:53am
Akebia proposes new dosing for oral anemia drug amid FDA dispute
Apr 3, 2023 11:34am